Mechanistic experiments showed that seRNA LOC100506178 bound to hnRNPK-MICAL2 to mediate EMT and exacerbated NPC metastasis, rendering it a novel prognostic biomarker and a therapeutic target for NPC patients. This evidence concerns the gene MICAL2 and nasopharyngeal carcinoma.